Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 133.58% | 40.41% | -51.96% | -35.55% | -11.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 133.58% | 40.41% | -51.96% | -35.55% | -11.61% |
| Cost of Revenue | -4.85% | -52.11% | -59.87% | -64.11% | -61.39% |
| Gross Profit | 62.49% | 85.80% | 61.91% | 69.07% | 68.72% |
| SG&A Expenses | -11.95% | -0.67% | -6.26% | -18.93% | -24.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.79% | -36.55% | -45.09% | -52.43% | -51.59% |
| Operating Income | 37.21% | 54.16% | 43.89% | 54.51% | 55.75% |
| Income Before Tax | 24.84% | 37.09% | 42.93% | 54.61% | 56.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.84% | 37.09% | 42.93% | 54.61% | 56.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -99.24% | -- | -88.67% | -76.20% | -62.71% |
| Net Income | 24.74% | 37.10% | 42.88% | 54.58% | 56.09% |
| EBIT | 37.21% | 54.16% | 43.89% | 54.51% | 55.75% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.30% | 91.72% | 96.65% | 95.69% | 93.65% |
| Normalized Basic EPS | 82.73% | 91.25% | 97.06% | 96.21% | 94.29% |
| EPS Diluted | 82.30% | 91.72% | 96.65% | 95.69% | 93.65% |
| Normalized Diluted EPS | 82.73% | 91.25% | 97.06% | 96.21% | 94.29% |
| Average Basic Shares Outstanding | 350.24% | 309.45% | 445.81% | 832.41% | 1,952.75% |
| Average Diluted Shares Outstanding | 350.24% | 309.45% | 445.81% | 832.41% | 1,952.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |